All lobbying filings

PRIME THERAPEUTICS

PRIME THERAPEUTICS filed a Q2 report for PRIME THERAPEUTICS on July 16, 2025.

Lobbying for PRIME THERAPEUTICS

All filings by PRIME THERAPEUTICS · Everything PRIME THERAPEUTICS has reported

Filing · LD-2 quarterly report Q2 report

Reporting period

2nd Quarter 2025

Apr 1 - June 30 · Posted Jul 16, 2025

Expenses

$100,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

Minnesota

Official filing document

Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 3

Health Issues

H.R.2214: The DRUG Act, provisions related to PBM compensation. S.891: The Bipartisan Health Care Act, provisions related to PBM regulation. H.R.10445 (118th Congress): Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers. H.R.5378 (118th Congress): Lower Cost, More Transparency Act. S.526 Pharmacy Benefit Manger Transparency Act of 2025, provisions related to transparency and pharmacy and PBM compensation. S.1339 PBM Reform Act (118th Congress): provisions related to PBM compensation.

Medicare/Medicaid

S.832: EPIC Act, provisions on eligibility for Medicare drug price negotiation. S.891: The Bipartisan Health Care Act, provisions related to PBM regulation. H.R.10445 (118th Congress): Further Consolidating Appropriations and Disaster Relief Supplemental Appropriations Act, Division E, Healthcare, provisions regulating pharmacy benefit managers. H.R.5378 (118th Congress): Lower Cost, More Transparency Act. H.R.1: The One Big Beautiful Bill (House version), provisions on PBM transparency, audit rights and payments.

Trade (domestic/foreign)

Tariffs on pharmaceuticals.

Bills named in this filing 8

H.R. 2214
DRUG Act
S. 891
Bipartisan Health Care Act
H.R. 10445
Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act, 2025
H.R. 5378
Lower Costs, More Transparency Act
S. 526
Pharmacy Benefit Manager Transparency Act of 2025
S. 1339
Pharmacy Benefit Manager Reform Act
S. 832
EPIC Act of 2025
H.R. 1
Lower Energy Costs Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.